日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Diverging effects of tumor necrosis factor inhibitors and conventional synthetic disease-modifying antirheumatic drugs on immunosenescence and inflammageing in rheumatoid arthritis: a cross-sectional analysis

肿瘤坏死因子抑制剂与传统合成疾病修饰抗风湿药物对类风湿关节炎免疫衰老和炎症衰老的不同影响：一项横断面分析

期刊:Immunity & Ageing
影响因子:5.6
doi:10.1186/s12979-025-00508-w
Schwarz, Tobias; Almanzar, Giovanni; Völkl, Sebastian; Feuchtenberger, Martin; Leierer, Johannes; Schmidt, Christian; Deininger, Frank; Tony, Hans-Peter; Schmalzing, Marc; Prelog, Martina
肿瘤
炎症
肿瘤免疫
炎症/感染
衰老
关节炎
免疫/内分泌
发表日期：2025
文献求助 收藏

Risk of major adverse cardiovascular events in patients with rheumatoid arthritis treated with conventional synthetic, biologic and targeted synthetic disease-modifying antirheumatic drugs: observational data from the German RABBIT register

德国 RABBIT 注册研究的观察性数据：接受传统合成、生物制剂和靶向合成疾病修饰抗风湿药物治疗的类风湿关节炎患者发生重大不良心血管事件的风险

期刊:RMD Open
影响因子:4.7
doi:10.1136/rmdopen-2023-003489
Meissner, Yvette; Schäfer, Martin; Albrecht, Katinka; Kekow, Joern; Zinke, Silke; Tony, Hans-Peter; Strangfeld, Anja
关节炎
发表日期：2023
文献求助 收藏

Subcutaneous abatacept for the treatment of rheumatoid arthritis in routine clinical practice in Germany, Austria, and Switzerland: 2-year retention and efficacy by treatment line and serostatus

在德国、奥地利和瑞士的常规临床实践中，皮下注射阿巴西普治疗类风湿性关节炎：按治疗线和血清状态划分的2年维持率和疗效

期刊:Clinical Rheumatology
影响因子:2.8
doi:10.1007/s10067-023-06649-x
Alten, Rieke; Tony, Hans-Peter; Bannert, Bettina; Nüßlein, Hubert; Rauch, Christiane; Connolly, Sean E; Chartier, Melanie; Lozenski, Karissa; Hackl, Roland; Forster, Adrian; Peichl, Peter
关节炎
发表日期：2023
文献求助 收藏

[Apps in rheumatology : Is there a need for an app in therapy for axial spondyloarthritis?]

【风湿病学应用：中轴型脊柱关节炎的治疗是否需要应用？】

期刊:Zeitschrift Fur Rheumatologie
影响因子:1
doi:10.1007/s00393-021-01104-1
Strunz, Patrick-Pascal; Maire, Maxime Le; Heusinger, Tobias; Hammel, Ludwig; Gernert, Michael; Schwaneck, Eva C; Callhoff, Johanna; Portegys, Jan; Schmalzing, Marc; Tony, Hans-Peter; Froehlich, Matthias
关节炎
发表日期：2023
文献求助 收藏

Calprotectin (S100A8/S100A9) detects inflammatory activity in rheumatoid arthritis patients receiving tocilizumab therapy

钙卫蛋白（S100A8/S100A9）可检测接受托珠单抗治疗的类风湿性关节炎患者的炎症活动。

期刊:Arthritis Research & Therapy
影响因子:4.6
doi:10.1186/s13075-022-02887-7
Gernert, Michael; Schmalzing, Marc; Tony, Hans-Peter; Strunz, Patrick-Pascal; Schwaneck, Eva Christina; Fröhlich, Matthias
S100A8
炎症
炎症/感染
S100A9
关节炎
发表日期：2022
文献求助 收藏

Effectiveness of Different Rituximab Doses Combined with Leflunomide in the Treatment or Retreatment of Rheumatoid Arthritis: Part 2 of a Randomized, Placebo-Controlled, Investigator-Initiated Clinical Trial (AMARA)

不同剂量利妥昔单抗联合来氟米特治疗或再治疗类风湿性关节炎的疗效：一项随机、安慰剂对照、研究者发起的临床试验（AMARA）的第二部分

期刊:Journal of Clinical Medicine
影响因子:2.9
doi:10.3390/jcm11247316
Koehm, Michaela; Foldenauer, Ann C; Rossmanith, Tanja; Alten, Rieke; Aringer, Martin; Backhaus, Marina; Burmester, Gerd R; Feist, Eugen; Kellner, Herbert; Krueger, Klaus; Müller-Ladner, Ulf; Rubbert-Roth, Andrea; Tony, Hans-Peter; Wassenberg, Siegfried; Burkhardt, Harald; Behrens, Frank
关节炎
发表日期：2022
文献求助 收藏

Lymphocyte subsets in the peripheral blood are disturbed in systemic sclerosis patients and can be changed by immunosuppressive medication

系统性硬化症患者外周血淋巴细胞亚群紊乱，免疫抑制药物可改变其组成。

期刊:Rheumatology International
影响因子:2.9
doi:10.1007/s00296-021-05034-8
Gernert, Michael; Tony, Hans-Peter; Schwaneck, Eva Christina; Gadeholt, Ottar; Fröhlich, Matthias; Portegys, Jan; Strunz, Patrick-Pascal; Schmalzing, Marc
细胞生物学
系统性硬化症
免疫/内分泌
发表日期：2022
文献求助 收藏

Responses to Ixekizumab in Male and Female Patients with Psoriatic Arthritis: Results from Two Randomized, Phase 3 Clinical Trials

伊克珠单抗治疗银屑病关节炎男性和女性患者的疗效：两项随机3期临床试验的结果

期刊:Rheumatology and Therapy
影响因子:2.9
doi:10.1007/s40744-022-00445-w
Eder, Lihi; Tony, Hans-Peter; Odhav, Satish; Agirregoikoa, Eva Galindez; Korkosz, Mariusz; Schwartzman, Sergio; Sprabery, Aubrey Trevelin; Gellett, Amanda M; Park, So Young; Bertram, Clinton C; Ogdie, Alexis
关节炎
银屑病
发表日期：2022
文献求助 收藏

Sarilumab reduces disease activity in rheumatoid arthritis patients with inadequate response to janus kinase inhibitors or tocilizumab in regular care in Germany

在德国，对于接受常规治疗但对 Janus 激酶抑制剂或托珠单抗反应不足的类风湿性关节炎患者，Sarilumab 可降低疾病活动度。

期刊:Rheumatology Advances in Practice
影响因子:2.1
doi:10.1093/rap/rkac002
Tony, Hans-Peter; Feist, Eugen; Aries, Peer Malte; Zinke, Silke; Krüger, Klaus; Ahlers, Jonas; Albrecht, Inka; Barrionuevo, Christian; Kalus, Stefanie; Burkhardt, Harald
信号转导
关节炎
发表日期：2022
文献求助 收藏

Induction of IL-9 in Peripheral Lymphocytes of Rheumatoid Arthritis Patients and Healthy Donors by Th17-Inducing Cytokine Conditions.

Th17诱导细胞因子条件下类风湿性关节炎患者和健康供体外周淋巴细胞中IL-9的诱导

期刊:Frontiers in Immunology
影响因子:5.9
doi:10.3389/fimmu.2021.668095
Heim Jana, Almanzar Giovanni, Schmalzing Marc, Gernert Michael, Tony Hans-Peter, Prelog Martina
细胞生物学
关节炎
T细胞
发表日期：2021
文献求助 收藏